ESR1 and neoplasm: We have previously shown that tumor phenotypic evolution during combination ribociclib therapy leads to the emergence of cell cycle reactivation through a shift from estrogen to alternative growth signal-mediated proliferation in this early-stage ER+ breast cancer population10.